Platt Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History

Platt Investment Counsel’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$491K	Buy	+8,525	New	+$490K	0.33%	10

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Platt Investment Counsel's BMY Position: Q2 2026 in Review

Platt Investment Counsel opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 8,525 shares worth $491K. The stake represents 0.33% of the portfolio and ranks #10 among its holdings.

2,502 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Platt Investment Counsel held 8,525 shares of Bristol-Myers Squibb worth $491K as of Q2 2026.
Bristol-Myers Squibb was a new Platt Investment Counsel position in Q2 2026.
Bristol-Myers Squibb made up 0.33% of Platt Investment Counsel's portfolio in Q2 2026, its #10 holding.
2,502 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Platt Investment Counsel's 13F filing for Q2 2026, filed 8 Jul 2026.